Email this article LONG-TERM RESULTS OF TARGET THERAPY WITH FIRST AND * SECOND-LINE TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- Authors: Vysotskaya L.L.1, Golenkov A.K.1, Trifonova E.V.1, Mitina T.A.1, Kataeva E.V.1, Chernykh Y.B.1
-
Affiliations:
- Moscow Regional Research and Clinical Institute
- Issue: No 41 (2015)
- Pages: 60-65
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/79
- DOI: https://doi.org/10.18786/2072-0505-2015-41-60-65
- ID: 79
Cite item
Full Text
Abstract
Aim: To assess long-term efficacy of firstand second-line tyrosine kinase inhibitors in non-selected patients with chronic myeloid leukemia in a real-life clinical setting.
Materials and methods: The assessment is based on long-term results of a prospective single center comparative clinical trial that was based on non-selected groups of 116 patients with various stages of chronic myeloid leukemia being treated with a first generation tyrosine kinase inhibitor imatinib, and of 44 patients being treated with a second generation tyrosine kinase inhibitor nilotinib. We analyzed all-cause mortality, progression-free survival from April 2005 to April 2013, with a median of the follow-up of 128 months.
Results: In 116 patients with chronic myeloid leukemia treated with imatinib, the Kaplan-Meier survival estimate was 120 months. In 44 patients at an early chronic phase, 5-year overall survival and progression-free survival was 93.2% and 8-year overall and progression-free survival was 79.5%. In 44 patients at a late chronic stage, 5-year overall and progression-free survival was 95.5%, 8-year overall and progression-free survival, 72.7%. In 28 patients at acceleration phase, 5-years overall survival was 78.6% and 8-year overall survival, 46%. Median of overall survival in patients treated with nilotinib was not reached. During 78.6 months of combination treatment with cytotoxic agents, tyrosine kinase inhibitors of the first (imatinib) and second line (nilotinib), overall survival was 100%.
Conclusion: In clinical practice, inclusion of patients with chronic myeloid leukemia and imatinib resistance (disease relapse) or imatinib intolerance into the treatment program with frontline therapy with general cytotoxic agents and thereafter with firstand second-line tyrosine kinase inhibitors significantly improves overall survival.
Keywords
About the authors
L. L. Vysotskaya
Moscow Regional Research and Clinical Institute
Author for correspondence.
Email: nora.mila@yandex.ru
Vysotskaya Lyudmila Leonidovna – PhD, Research Fellow, Department of Clinical Hematology and Immune Therapy Russian Federation
A. K. Golenkov
Moscow Regional Research and Clinical Institute
Email: nora.mila@yandex.ru
Golenkov Anatoliy Konstantinovich – MD, PhD, Professor, Head of Department of Clinical Hematology and Immune Therapy Russian Federation
E. V. Trifonova
Moscow Regional Research and Clinical Institute
Email: nora.mila@yandex.ru
Trifonova Elena Viktorovna – PhD, Senior Research Fellow, Department of Clinical Hematology and Immune Therapy Russian Federation
T. A. Mitina
Moscow Regional Research and Clinical Institute
Email: nora.mila@yandex.ru
Mitina Tat'yana Alekseevna – PhD, Senior Research Fellow, Department of Clinical Hematology and Immune Therapy Russian Federation
E. V. Kataeva
Moscow Regional Research and Clinical Institute
Email: nora.mila@yandex.ru
Kataeva Elena Vasil'evna – PhD, Senior Research Fellow, Department of Clinical Hematology and Immune Therapy Russian Federation
Yu. B. Chernykh
Moscow Regional Research and Clinical Institute
Email: nora.mila@yandex.ru
Chernykh Yuliya Borisovna – Research Fellow, Department of Clinical Hematology and Immune Therapy Russian Federation
References
- Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11(9):3425–32.
- Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.
- Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8(7):2167–76.
- Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005;103(8):1659–69.
- Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 2006;20(4):664–70.
- Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.
- Larson RA, Kim DW, Issaragrilsil S, le Coutre P, Dorlhiac-Llacer PE, Etienne G, Clark RE, Flinn I, Nakamae H, Hochhaus A, Saglio G, Kantarjian HM, Donohue B, Deng W, Menssen HD, Hughes TP. Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of ENESTnd [abstract]. Blood. 2014;124(21):4541.
- Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27(1):107–12. doi: 10.1038/leu.2012.181.
- ARIAD Pharma Reports Approval Of Iclusig In Canada – Quick Facts. Accessed: 4/6/2015 7:46 AM ET. Available from: http://cml-stop. ru/,http://www.ariad.com, http://www.iclusig. com
- Vysotskaya L, Golenkov A, Trifonova E, Chernykh Y, Lutskaya Т, Inyutkina N, Chucavina M. Efficacy of the expanded treatment program with imatinib mesylate in 109 patients with chronic myeloid leukemia (CML). Haematologica. 2007;92(Suppl 1):532. Abstr. 1496.
- Высоцкая ЛЛ, Трифонова ЕВ, Голенков АК. Эффективность лечения хронического миелолейкоза Гливеком в широкой клинической практике. Гематология и трансфузиология. 2008;53(6):17–22.
- Vysotskaya L, Golenkov A, Trifonova E, Chernykh Y, Lutskaya Т. Clinical aspects of the expanded treatment program with imatinib mesylate in 132 patients with chronic myeloid leukemia. Abstrасt book of 19th International Congress on Anticancer Treatment. Paris, France, 5–8 February 2008. Paris; 2008. p. 289. Abstr. 26.
- Голенков АК, Высоцкая ЛЛ, Трифонова ЕВ. Эффективность программы лечения хрони ческого миелолейкоза Гливеком в широкой клинической практике. Альманах клинической медицины. 2008;18:9–13.
- Голенков АК, Высоцкая ЛЛ, Трифонова ЕВ, Гуров АН. Организационные и клинические аспекты лечения хронического миелолейкоза Гливеком в широкой клинической практике. Вестник гематологии. 2008;4(4):29–32.
- Голенков АК, Высоцкая ЛЛ, Трифонова ЕВ, Митина ТА, Луцкая ТД, Катаева ЕВ, Дудина ГА, Черных ЮБ, Буравцова ИВ, Гуров АН, Горенков РВ. Эффективность лечения больных хроническим миелолейкозом иматинибом в широкой клинической практике. Онкогематология. 2012;(3):17–21.
- Golenkov AK, Vysotskaya LL, Tryphonova EV, Mytyna TA, Lutskaya TD, Chernyh UB, Kataeva EB, Dudina GA, Buravtsova IV. Сytogenetic response in correlation with imatinib median daily dose in non-selected patients with chronic myeloid leukemia (CML) receiving imatinib in routine practice. ELN Frontiers Meeting 2012. Myeloid Neoplasms: Approaching cure. Istanbul, Turkey, 9–11 November 2012. Abstr. 9. p. 10. Available from: http://www.leukemia-net. org/content/home/eln_meetings/eln_frontiers_meeting/e10295/infoboxContent10296/ ELN_Abstracts_2012.pdf
- Vysotskaya LL, Golenkov AK, Triphonova EV, Mitina EV, Lutskaya TD, Chernyh UB, Kataeva EB, Dudina GA. Intermittent imatinib therapy in patients with chronic myeloid leukemia is the real basis of routine clinical practice. Abstracts of ELN Frontiers Meeting 2014. Berlin, Germany, 16–19 October 2014. p. 26. Abstract 29. Available from: http://www.leukemia-net.org/content/home/eln_meetings/ eln_frontiers_meeting/e10501/infoboxContent10502/NORE1401ELNFrontiers2014AbstractbookletPP2.pdf
- Vysotskaya L, Golenkov A, Tryphonova E, Mitina T, Lutskaya T, Chernyh Y, Kataeva E, Dudina G. Efficacy of intermittent imatinib therapy in patients with chronic myeloid leukemia is the real basis of routine clinical practice. 36th EORTC-Pamm Meeting. Marseille, France, 21–24 January 2015. Bioguided Oncology, 2015;33:111.
- Высоцкая ЛЛ, Голенков АК, Трифонова ЕВ, Митина ТА, Луцкая ТД, Катаева ЕВ, Дудина ГА, Захаров СГ, Буравцова ИВ, Черных ЮБ, Белоусов КА. Эффективность ингибитора тирозинкиназ второй линии в лечении маркерно-рецидивных/резистентных хронических миелолейкозов. В: Материалы XXII конгресса «Человек и лекарство». Москва, Россия, 6–10 апреля 2015 М.; 2015. с. 30.
Supplementary files
